An observational study in Chronic Pancreatitis, sponsored by Asian Institute of Gastroenterology, India. Status unknown at 1 site in India. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-02-08.
Sponsored by Asian Institute of Gastroenterology, India · Observational
Chronic pancreatitis (CP) is characterised by recurrent abdominal pain. The pathological hallmarks of CP is pancreatic stellate cell activation that results in persistent inflammation and progressive fibrosis. It has been shown in various clinical and experimental studies that with disease progression there could be pancreatic neural inflammation, spinal sensitization and eventually alteration in the pain modulating architecture within the brain (widespread sensitization). These events result in different types of pain (nociceptive and neuropathic) in patients with CP, which may dynamically change during disease progression.
Since the treatment for different mechanisms are unique, it becomes important to identify the predominant type of pain. Recently, pancreatic quantitative sensory testing (P-QST) has emerged as a valuable tool to identify different types of sensitization. This facility is currently available only in select centers and is being conducted under research protocols.
In this study, we propose to: 1. evaluate the patterns of pain in CP and the triggers; 2. identify clinical surrogates of sensitization, i.e. neuropathic pain.
The ultimate goal is to apply the best possible pain management strategy based on our research findings for patients with CP in a personalised manner.
751 studies on the registry are indexed under Pancreatitis; 180 are open to participants now.
This study's planned enrollment of 500 is above the median of 179 across 276 observational studies indexed under Pancreatitis.
Browse Pancreatitis studies →Asian Institute of Gastroenterology, India is the lead sponsor of 132 studies on the registry; 59 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with documented CP will be screened for enrolment criteria. Those fulfilling criteria will be enrolled after written informed consent.
Exclusion Criteria:
Detailed clinical history including demographic details, pain details (character, pattern, location, change in character, involvement of new areas), duration of disease, co-morbidities, family history, adverse life events, sleep details, details of stress/anxiety.
Thorough clinical examination, anthropometric measurement, assessment of pain (Izbicki score, Visual analog scale, modified brief pain inventory, pain catastrophising score, painDetect)
Use of the EORTC QLQ c30 with PAN 28 to evaluate quality of life
Use of Beck depression inventory and Hospital Anxiety Depression score to evaluate depression and anxiety
Pancreatic quantitative sensory testing will be performed to evaluate temporal summation, pain detection threshold, pain tolerance threshold, and conditioned pain modulation.
Type of pain
The type of pancreatic pain, i.e nociceptive or neuropathic will be determined
Time frame: 18 months
Quality of life
EORTC QLQ c30 score
Time frame: 18 months
Mental status
Depression and anxiety will be determined
Time frame: 18 months
Neural sensitization
Presence of localised and widespread sensitisation will be determined.
Time frame: 18 months
Plan to share: Undecided
This study is status unknown, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Asian Institute of Gastroenterology, India